Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)

Customer Reviews
Cat. No. / Size
Price
Qty
BEB-Y12-100ug
$355.00
BEB-Y12-1mg (500ug X 2)
$2695.00
ETA of in-stock products:2 business days

Product Details

  • Source

    Anti-Bevacizumab Antibody (AY12) is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.

  • Antibody Type

    Hybridoma Monoclonal

  • Clone

    AY12

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Immunogen

    Bevacizumab

  • Specificity

    Recognizes Bevacizumab specifically.

  • Application

    Application
    Recommended Usage
    ELISA
    1:5-1:50
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 5%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in Tris (pH 7.5) containing 100 mM Glycine, 25 mM Arginine, 150 mM NaCl and 0.01% Tween80, with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-ELISA

     Bevacizumab ELISA

    Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 5 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL (QC tested).

    Protocol
  •  Bevacizumab ELISA

    Demonstration of the specificity of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) to the bevacizumab.

    Protocol
  •  Bevacizumab ELISA

    Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.

    Protocol
  • Bioactivity-SPR

     Bevacizumab SPR

    Anti-Bevacizumab Antibody (AY12) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.

    Protocol

Customer Reviews
Writing Reviews

Background

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Recent Advances

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background